Gradient Capital Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,532 shares of the company’s stock after selling 315 shares during the quarter. Gradient Capital Advisors LLC’s holdings in Johnson & Johnson were worth $778,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in Johnson & Johnson by 1.5% in the first quarter. Geode Capital Management LLC now owns 38,965,156 shares of the company’s stock valued at $5,100,421,000 after acquiring an additional 572,077 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 10.8% in the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after purchasing an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in shares of Johnson & Johnson by 7.7% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares during the period. Capital World Investors boosted its position in shares of Johnson & Johnson by 182.9% in the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after purchasing an additional 13,703,905 shares during the last quarter. Finally, Morgan Stanley grew its stake in shares of Johnson & Johnson by 0.3% during the first quarter. Morgan Stanley now owns 20,801,433 shares of the company’s stock worth $2,727,694,000 after purchasing an additional 54,563 shares during the period. 68.44% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have issued reports on the company. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Citigroup lifted their price objective on shares of Johnson & Johnson from $165.00 to $170.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. UBS Group downgraded shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and lowered their target price for the company from $163.00 to $160.00 in a research note on Tuesday, April 28th. SVB Leerink reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Barclays raised their price objective on Johnson & Johnson from $173.00 to $182.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 29th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $163.38.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.27% of the stock is owned by insiders.
NYSE:JNJ opened at $145.76 on Friday. The stock has a 50-day simple moving average of $144.04 and a 200 day simple moving average of $144.14. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The company has a market cap of $386.60 billion, a PE ratio of 21.31, a PEG ratio of 3.25 and a beta of 0.69. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The company had revenue of $18.34 billion for the quarter, compared to the consensus estimate of $17.73 billion. During the same period last year, the company earned $2.58 earnings per share. The firm’s revenue was down 10.8% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 7.85 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio is 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: What is insider trading?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.